- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne - - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 ...

The ocean's biodiversity is a key source of marine-derived compounds, fueling pharmaceutical innovations and drug discovery ...

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...

The FDA has issued a Complete Response Letter regarding the NDA for govorestat for the treatment of classic galactosemia.

If you are an Applied Therapeutics investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

President-elect Donald Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA at Mar-a-Lago for a dinner with ...

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:APLT). Such ...

Applied Therapeutics’ CEO Shoshana Shendelman has a debilitating credibility problem: She repeatedly misled investors prior ...

The National PKU Alliance (NPKUA), in collaboration with a coalition of PKU-related patient advocacy organizations, announces the TruePKU initiative, a groundbreaking effort to highlight the lived ...

While Applied Therapeutics has vowed to reapply or appeal the FDA’s recent rejection of its rare disease candidate govorestat ...

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical ...

Applied Therapeutics has been sent a warning letter from the FDA over a clinical trial of its rare disease therapy govorestat ...